IL25 and breast cancer: As we previously reported that 1 to 10 ng/ml of IL-17A was very potent at inhibiting Docetaxel induced cell death in various human breast cancer cell lines12.The results shown in Fig. 4 indicated that pretreatment of MCF-7, T47D or primary tumor cells IJG-1731 with 1 to 10 ng/ml of IL-17E consistently results in decreased Docetaxel-induced cell death.